Hikma Pharmaceuticals said last year that it would shell out more than $1 billion for Boehringer Ingelheim's U.S.-based generics business, Roxane Labs, to gain ground in noninjectable generics. But now, Hikma is slashing its offer price for the deal after catching wind of Roxane's disappointing 2015 sales.
Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance.
Last September, a big study showed that Eli Lilly and Boehringer Ingelheim's SGLT2 diabetes drug, Jardiance, could lower cardiovascular risks. Now, the companies are one step closer to adding that study data to the drug's label--a win that could rock the marketplace, not only in the SGLT2 drug class, but in competitor categories like DPP-4 meds.
What do fish and atrial fibrillation have in common? AFib feels like a fish fluttering in your chest, according to patients interviewed by Germany-based drugmaker Boehringer Ingelheim. That was the insight that inspired a newly launched ad campaign for clot-fighter Pradaxa, featuring computer-generated fish.
German pharma giant Boehringer Ingelheim is wagering up to $262 million on a discovery-stage project with the struggling Arena Pharmaceuticals, hoping to spotlight new treatments for central nervous system disorders.
Germany's Boehringer Ingelheim has been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its revenues. After doing deals to bolster its top line, it will now spend some money on manufacturing in hopes of riding the biopharma boom to greater heights, adding about 400 jobs in the process.
Biologics manufacturing has been expanding as drugmakers develop more and more cell-based drugs with special capabilities. Boehringer Ingelheim is jumping on the buildup bandwagon with plans to spend half a billion euros on a new plant in Austria.
The FDA is putting an oral lung cancer drug from Boehringer Ingelheim on its inside track, promising to accelerate development of a new EGFR mutation-specific tyrosine kinase inhibitor that could quickly rival competing therapies from AstraZeneca and Clovis Oncology. And Boehringer is promising to hustle its way through a pivotal program with an eye to a near-term launch.
Partners Eli Lilly and Boehringer Ingelheim inched closer to challenging Sanofi's best-selling insulin, winning FDA approval for their take on the blockbuster Lantus as they wait for its U.S. patent protection to expire.
Is the swap destined to be pharma's next M&A trend? When dealmakers tot up the advantages of Sanofi and Boehringer Ingelheim's asset-trade talks--and add them to the big GlaxoSmithKline-Novartis swap-out earlier this year--they might follow up with barter arrangements of their own, M&A experts say.